SafeHeal, a Paris, France- and Tampa, FL-based colorectal cancer surgery company, raised €35M in Series C equity funding.
The round was led by Solar Eclipse with new investors Gideon Strategic Partners and M&L Healthcare, part of M&L Group, and returning investors Sofinnova Partners.
The company intends to use the funds to complete its IDE Pivotal study and accelerate preparation for commercial launch of their lead technology, Colovac.
Led by CEO and President Chris Richardson, SafeHeal is a clinical-stage medical device company developing Colovac, a device intended as an alternative to diverting ostomy in patients undergoing colorectal surgery. It is a flexible endoluminal bypass sheath designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for 7-10 days, until the body’s natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure.
FinSMEs
01/05/2025